Exploring how modifying antibodies can reduce inflammation.
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
This study is looking at how a special change to antibodies can help reduce inflammation in autoimmune diseases, and it aims to see if using a specific enzyme to make these changes can improve symptoms for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11042765 on NIH RePORTER |
What this research studies
This research investigates the role of a specific modification of antibodies, known as sialylation, in reducing inflammation associated with autoimmune diseases. By administering a specialized enzyme, the study aims to enhance the sialylation of certain antibody types, which may lead to improved anti-inflammatory effects. The research will involve examining how these modified antibodies interact with immune cells and their potential to alleviate symptoms in models of autoimmune conditions. Patients may benefit from a deeper understanding of how their immune responses can be regulated through antibody modifications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases, particularly those with conditions characterized by high inflammation.
Not a fit: Patients with non-autoimmune inflammatory conditions or those not responding to antibody-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce inflammation in patients with autoimmune diseases.
How similar studies have performed: Previous research has shown promising results in modifying antibodies for therapeutic purposes, indicating potential success for this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Anthony, Robert Mccullough — Massachusetts General Hospital
- Study coordinator: Anthony, Robert Mccullough
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.